Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

odanacatib

Known as: (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide 
An inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K… Expand
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Biphenyl Compounds
Bone Resorption InhibitionCathepsins

Narrower (1)

MK-0822

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Osteoporosis treatment: recent developments and ongoing challenges.
Osteoporosis is an enormous and growing public health problem. Once considered an inevitable consequence of ageing, it is now… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Merck &Co. drops osteoporosis drug odanacatib
  • Asher Mullard
  • Nature Reviews Drug Discovery
  • 2016
    • Corpus ID: 10186583
drugs with new mechanisms of action. Novel drugs accounted for 27% of the phase III cardiovascular candidates in 1990, and 57% of… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
SummaryOdanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate… Expand
  • table 1
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that is highly expressed by osteoclasts. In this 2-year… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys.
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK) currently being developed as a once-weekly… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral density (BMD) and decreased bone… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Odanacatib (ODN) is a selective, potent and reversible inhibitor of cathepsin K (CatK) that inhibits bone loss in postmenopausal… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
BACKGROUND Metastatic bone disease (MBD) is a frequent complication in patients with breast cancer and is associated with… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen. Odanacatib selectively and reversibly… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE